Toothpaste Has No Structure/Function Safe Harbor

who is 21 cfr 101.93 actually written for?

21 CFR 101.93 is written for dietary supplements making structure/function statements under DSHEA, not for every health-adjacent consumer product with careful wording. The opening frame matters because it points back to 21 U.S.C. 343(r)(6), the supplement provision. A structure/function claim, meaning a claim about normal body structure or function, can sit inside that lane only when the product itself is a dietary supplement and the required conditions are met.

The required disclaimer is not a universal shield. Under 21 CFR 101.93, the label statement says: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." That sentence belongs to lawful supplement structure/function claims; it doesn't make a toothpaste, rinse or oral gel into a supplement.

We checked this distinction because buyers routinely borrow the supplement playbook for oral care product ad compliance. The safer mental model is narrower: first ask whether the product is a dietary supplement, then ask whether the claim stays inside structure/function, then ask whether FTC substantiation exists. If the answer to the first question is no, the 101.93 route is already gone.

why does the safe harbor disappear the moment the format is not a supplement?

The safe harbor disappears because DSHEA protects a class of product, not a style of sentence. A capsule that bears or contains a qualifying dietary ingredient can use 101.93 if the claim stays in bounds; a toothpaste, rinse or gel is judged under the drug and cosmetic framework instead. That is the piece many media buyers skip when they move from a ClickBank-style supplement offer into oral care.

The same mistake shows up in adjacent verticals, which is why our structure/function vs disease claims in supplement ads page separates claim type from product category. For supplements, FDA asks whether the statement claims an effect on a disease, characteristic symptoms or disease context. For non-supplements, FDA can ask the simpler question: is the product intended to affect the structure or function of the body?

FDA states the product-form asymmetry plainly on cosmetics: "products intended to affect the structure or function of the body, such as the skin, are drugs" per FDA's anti-aging products page. Oral care has the same operational lesson. A phrase that sounds like maintenance copy may still describe intended body effect when it sits on a rinse or paste.

what did fda cite as evidence of intended use in the stellalife letter?

FDA cited the StellaLife oral-care claims as intended-use evidence rather than treating them as harmless wellness copy. The fact pack identifies the September 16, 2025 StellaLife, Inc. warning letter, CMS 712804, as reproducing phrases such as "promote healthy gums, maintain oral health, and freshen your breath" inside the evidence block. That placement is the signal: FDA did not leave maintenance-register language outside the drug analysis.

We could not verify the full StellaLife letter text from the source list supplied here because no StellaLife URL was printed with the fact. The item that would settle it is the FDA warning-letter page for CMS 712804 showing the complete quoted evidence block.

The operational point does not depend on a dramatic disease phrase. Intended use, meaning the seller's objective purpose for the product, can be shown by labeling, advertising, oral or written statements, or distribution context under 21 CFR 201.128. If your landing page, product name, channel placement and social proof all point toward gum disease, the soft verb at the center of the sentence won't carry the defense.

how does 201(g)(1)(c) make structure or function intent its own drug route?

Section 201(g)(1)(C) makes structure or function intent its own drug route because the drug definition is not limited to disease treatment. FDA's standard enforcement chain treats a product as a drug if it is intended to diagnose, cure, mitigate, treat or prevent disease and/or to affect the structure or function of the body. For a non-supplement oral product, that second half is enough to matter.

This is the claim most oral marketers push back on: "supports healthy gums" can be worse on toothpaste than on a capsule. On a supplement, the phrase may still need 101.93 compliance and FTC substantiation. On a paste or rinse, the same phrase can become evidence that the product is intended to affect tissue in the mouth, and no DSHEA safe harbor travels with it.

FTC still sits on top of that analysis. Its 2022 Health Products Compliance Guidance says, "The FTC doesn't have a parallel notification requirement," but both agencies require substantiation before the claim runs. The practical result is two gates, not one: FDA classification decides whether the product is an unapproved drug, while FTC asks whether the ad claim is truthful, not misleading and backed by competent evidence.

which oral phrasing did fda reproduce that copywriters assume is safe?

FDA reproduced oral maintenance phrasing that copywriters often assume is safe: gum support, oral-health maintenance, fresh breath and similar low-drama language. In the StellaLife fact, FDA quoted "promote healthy gums, maintain oral health, and freshen your breath." In the Health and Natural Beauty USA Corp. fact, FDA quoted "to help maintain healthy gums." The problem is not that those words always fail; the problem is that product format changes what those words do.

The comparison is easiest to see as a buyer checklist before creative approval:

does the offer's format decide the rule set before the copy does?

Yes, the offer's format decides the rule set before the copy does. A dietary supplement, a toothpaste, a mouth rinse, a homeopathic oral gel and a topical cosmetic do not enter the same legal lane just because the copywriter uses the word "support." If you classify the offer incorrectly at intake, every compliant-sounding hook after that may be built on the wrong rule.

That is why niche selection and format selection belong in the same buying conversation, not in separate departments. Our product niche selection notes focus on room to grow, but in oral care the missing question is whether the product type gives you a lawful claims route at all. A crowded but lawful supplement lane can be easier to operate than an oral product whose desired claims turn it into a drug.

FTC's substantiation rule also follows the claim, not the media buyer's intent. The agency says health-benefit substantiation will generally need randomized, controlled human clinical testing, and the evidence must be sufficient when viewed against the whole body of reliable science. That means a buyer cannot fix a weak oral-care page by moving budget from Meta to Google or by swapping a VSL, video sales letter, for advertorial copy.

what changes when the same claim moves from a capsule to a rinse?

When the same claim moves from a capsule to a rinse, the supplement disclaimer stops being available and the structure/function phrase can become drug evidence. A capsule with a qualifying dietary ingredient may use 101.93 if it avoids disease claims, carries the disclaimer, notifies FDA within 30 days of first marketing and has substantiation. A rinse has to defend the product's intended use without that supplement-specific route.

The platform layer changes too. Meta's Unacceptable Business Practices policy bars ads that "use deceptive or exaggerated claims about health-related benefits of a product or service to mislead people," per Meta's policy page. Google also treats health as a sensitive interest category, which restricts audience tools. Your ad account problem often starts upstream, with the product classification and the landing-page claims.

This is why borrowed supplement copy is dangerous in oral care. A buyer may see "supports healthy gums" as conservative because it avoids periodontal disease. FDA may see the same sentence on a mouth rinse as evidence that the product is intended to affect gum tissue. Those are not semantic differences; they are different legal pathways.

how should a buyer classify an oral offer before writing a single hook?

A buyer should classify an oral offer by product form, intended use, evidence, channel policy and operational survivability before writing a single hook. Start with form: supplement capsule, toothpaste, rinse, gel, strip, device or cosmetic. Then map the desired claim to the governing lane. If the desired angle requires treating, preventing, repairing or reversing an oral condition, the campaign is not merely a copy problem.

Next, check the public record. We counted the supplied oral-care facts as format-driven, not phrasing-driven, because both StellaLife and Health and Natural Beauty USA Corp. reportedly had maintenance-style copy reproduced by FDA as intended-use evidence. That is the part your media plan has to price in before buying tests, ordering creative or approving affiliate pages.

Finally, separate legal clearance from platform clearance. An ad can be lawful enough to argue with counsel and still be rejected by Meta, Google or TikTok for health-benefit exaggeration, personal-attribute targeting or destination content. If you are sourcing from a network, our ClickBank safety page is relevant for the same reason: the network listing is not the compliance review.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Bladder and Pelvic Floor Offers: Market Map and Claim Limits, Arthritis-Adjacent Offers: Selling to a Diagnosed Pain Buyer, Toenail Fungus Offers: Visual Proof Versus Platform Rules, Brain Health Offers: The Senior Market and Its Hard Compliance Ceiling, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.